SCHEMBL20203533

SCHEMBL20203533

CSc1ncc2cc(COC(=O)c3ccccc3)nc(-c3ccoc3)c2n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 3/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 3/20 0.36
NTRK1 P04629 1/20 0.35
ALOX5 P09917 1/20 0.35
HPGD P15428 1/20 0.34
THRB P10828 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 1/20 0.33
PKM P14618 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
LMNA P02545 2/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23733423 0.89 TP53 (0.45) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL23733436 0.86 MAPT (0.36) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL20203627 0.86 RXFP1 (0.43) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL20203626 0.86 TP53 (0.40) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL20203536 0.84 POLB (0.38) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL20203618 0.82 TDP1 (0.39) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL20037634 0.81 TDP1 (0.43) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL18291265 0.81 KMT2A (0.42) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL31164152 0.81 KMT2A (0.42) TP53TDP1ALDH1A1POLBMAPT
SCHEMBL20203620 0.79 JAK2 (0.40) TP53TDP1ALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 TP53 176/4885TDP1 814/4885ALDH1A1 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.